Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system
Frontiers in Cellular and Infection Microbiology · 2025
DOI: 10.3389/fcimb.2025.1609409 ↗Kurz gefasst
Fachartikel in der Zeitschrift Frontiers in Cellular and Infection Microbiology, 2025. Verfasst von Yuhang Zhou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China. Hauptthemen laut MEDLINE: Pharmacovigilance, Hepatitis B Vaccines, Hepatitis A Vaccines, Adverse Drug Reaction Reporting Systems. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Hepatitis A Inactivated and Hepatitis B (Recombinant) Vaccine (Hep AB) was approved for use in 2001. Hep AB demonstrates satisfactory efficacy in protecting the public from hepatitis virus infections. However, there is a lack of recent real-world report on its adverse events (AEs).
Methods
We retrieved US AE reports related to Hep AB vaccination from VAERS for the period 2020-2024. We used four algorithms: Reporting Odds Ratio (ROR), Proportional Reporting Ratio (PRR), Bayesian Confidence Propagation Neural Network (BCPNN) and Multi-Item Gamma-Poisson Shrinkage (MGPS) to examine AE signals. The ROR and PRR algorithms have higher sensitivity but lower specificity. However, BCPNN and MGPS compensate for this limitation. Combining all four algorithms helps reduce false-positive signals. In addition to the general population, we also focused on reports stratified by gender.
Results
We retrieved 1,640 eligible reports from VAERS. In the general population, we identified two AE signals at the System Organ Classification (SOC) level. Additionally, we found 39 AE signals at the Preferred Term (PT) level. Among these, endocrine disorders were identified for the first time as AE signals. In the subsequent gender stratified analysis, more AE signals were identified in females compared to males. Notably, signals for endocrine disorders (autoimmune thyroiditis and Graves’ disease) were detected in females, whereas no such signals were found in males.
Conclusions
We conducted a comprehensive examination of the recent AE reports for Hep AB and identified unexpected AEs, particularly in females. These findings will provide valuable insights into future evidence-based surveillance strategies of Hep AB.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Breast Medicine 1, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China.
- Department of Pharmacology, Cancer Hospital of China Medical University, Liaoning Cancer Hospital, Shenyang, China.
- Department of Breast Medicine, Cancer Hospital of Dalian University of Technology, Liaoning Cancer Hospital, Shenyang, China.
Zitieren
APA
Zhou, Y., Wang, Y., Feng, Y., Zhang, H., Sun, T., & Xu, J. (2025). Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system. Frontiers in Cellular and Infection Microbiology. https://doi.org/10.3389/fcimb.2025.1609409
Vancouver
Zhou Y, Wang Y, Feng Y, Zhang H, Sun T, Xu J. Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system. Frontiers in Cellular and Infection Microbiology. 2025. doi:10.3389/fcimb.2025.1609409
BibTeX
@article{Zhou2025,
author = {Zhou, Yuhang and Wang, Yue and Feng, Yun and Zhang, Huiyue and Sun, Tao and Xu, Junnan},
title = {Real-world pharmacovigilance reports of hepatitis A inactivated and hepatitis B (recombinant) vaccine: insights from disproportionality analysis of the vaccine adverse event reporting system},
journal = {Frontiers in Cellular and Infection Microbiology},
year = {2025},
doi = {10.3389/fcimb.2025.1609409}
}
EUVIMED